NEW YORK, Oct. 20 (GenomeWeb News) - Sequenom today said it has acquired from Isis Innovation exclusive rights in certain countries to non-invasive prenatal diagnostic intellectual property.
The IP, which is covered in the
Financial terms include up-front fees, milestone payments, and royalties on product sales. Isis is the tech-transfer company of the University of Oxford.
"The licensed rights enable the development and performance of tests on any relevant platform, including [Sequenom's flagship] MassArray system," Harry Stylli, Sequenom's president and CEO, said in a statement.